Exploring the use of tyrosine kinase inhibitors (TKIs) in the management of HER2positive metastatic breast cancer post trastuzumab emtansine (TDM1) therapy failure: Insights from a real-world study

被引：0
|
作者：
Yin, Yongmei
Sun, Chunxiao
Hua, Yijia
Jin, Nan
Li, Wei
Huang, Xiang
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO4-04-06
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO4-04-06
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Use and Outcomes of Trastuzumab Deruxtecan in HER2-positive and HER2-low Metastatic Breast Cancer in Real-World Setting: A Nationwide Cohort Study
    Jourdain, Hugo
    Desplas, David
    Mansouri, Imene
    Zureik, Mahmoud
    Di Meglio, Antonio
    Haddy, Nadia
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 531 - 531
  • [22] Real world data on treatment patterns before and after reporting of the KATHERINE trial: A phase 3 study of adjuvant Ado-trastuzumab emtansine (TDM1) versus trastuzumab in early stage HER plus breast cancer
    Margolis, Neil
    Kozlovsky, Vlad
    Flood, William
    Reddy, Sandeep
    CANCER RESEARCH, 2020, 80 (04)
  • [23] Real-world survival outcomes associated with use of pertuzumab and trastuzumab emtansine (T-DM1) for HER2-positive (HER2+) metastatic breast cancer (MBC) in Brazilian private healthcare setting.
    Dienstmann, Rodrigo
    Cruz, Heloisa
    Goncalves, Aline Coelho
    Pinto de Andrade, Diocesio Alves
    Rubini Liedke, Pedro Emanuel
    Costa, Rafael Brant
    Dantas Loures da Costa, Mario Alberto
    Boukai, Alexandre
    Paes, Flavia Rocha
    Landeiro, Luciana G.
    Gimenes, Daniel Luiz
    Magalhaes, Maria Cristina Figueroa
    Andrade de Resende, Cristiano Augusto
    Reinert, Tomas
    Aguiar Junior, Pedro N.
    Paes, Rafael
    Costa e Silva, Matheus
    Ferrari, Bruno Lemos
    Mano, Max S.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [24] Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry
    Lux, Michael P.
    Nabieva, Naiba
    Hartkopf, Andreas D.
    Huober, Jens
    Volz, Bernhard
    Taran, Florin-Andrei
    Overkamp, Friedrich
    Kolberg, Hans-Christian
    Hadji, Peyman
    Tesch, Hans
    Haeberle, Lothar
    Ettl, Johannes
    Lueftner, Diana
    Wallwiener, Markus
    Mueller, Volkmar
    Beckmann, Matthias W.
    Belleville, Erik
    Wimberger, Pauline
    Hielscher, Carsten
    Geberth, Matthias
    Abenhardt, Wolfgang
    Kurbacher, Christian
    Wuerstlein, Rachel
    Thomssen, Christoph
    Untch, Michael
    Fasching, Peter A.
    Janni, Wolfgang
    Fehm, Tanja N.
    Wallwiener, Diethelm
    Schneeweiss, Andreas
    Brucker, Sara Y.
    CANCERS, 2019, 11 (01):
  • [25] Real-World Data of Triplet Combination of Trastuzumab, Lapatinib, and Chemotherapy in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study
    Li, Yi
    Gong, Chengcheng
    Lu, Qianyi
    Zhou, Zhaochun
    Luo, Ting
    Li, Wei
    Li, Gang
    Ge, Rui
    Xu, Fei
    Wang, Biyun
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [26] REAL-WORLD DATA OF TRIPLET COMBINATION OF PYROTINIB, TRASTUZUMAB, AND CHEMOTHERAPY IN HER2-POSITIVE METASTATIC BREAST CANCER: A MULTICENTER, RETROSPECTIVE STUDY
    Wang, Biyun
    You, Shuhui
    Xie, Yizhao
    Sang, Die
    Xu, Fei
    Luo, Ting
    Yuan, Peng
    BREAST, 2023, 71 : S52 - S52
  • [27] Real-world data of triplet combination of pyrotinib, trastuzumab, and chemotherapy in HER2-positive metastatic breast cancer: a multicenter, retrospective study
    You, Shuhui
    Sang, Die
    Xu, Fei
    Luo, Ting
    Yuan, Peng
    Xie, Yizhao
    Wang, Biyun
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [28] Real-World Analysis of the Efficacy and Safety of a Novel Irreversible HER2 Tyrosine Kinase Inhibitor Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer
    Sun, Ying
    Chen, Beibei
    Li, Jisheng
    Peng, Ling
    Li, Shuguang
    Yu, Xuejun
    Li, Li
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 7165 - 7174
  • [29] Real-world outcomes from the systemic use of CDK 4/6 inhibitors (CDKIs) in the management of ER positive (+) HER2 negative (-) metastatic breast cancer (mBC).
    DeSouza, Karen
    Yeo, Daniel
    Diossy, Maria
    Umar, Sumbal
    Gore, Emma
    Trivedi, Sachin
    Anand, Anjana
    Madhusudan, Srinivasan
    Khan, Sarah
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [30] Real-world Outcomes of Dual HER2 Blockade Therapy in Metastatic HER2-Positive Breast Cancer: from Induction to Maintenance
    Krizic, Marija
    Popovic, Marina
    Silovski, Tajana
    Grbin, Dorotea
    Plavetic, Natalija Dedic
    DRUGS-REAL WORLD OUTCOMES, 2024, 11 (03) : 413 - 423
12345